J
Jonathan S. Reiner
Researcher at George Washington University
Publications - 48
Citations - 2191
Jonathan S. Reiner is an academic researcher from George Washington University. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 18, co-authored 45 publications receiving 2044 citations. Previous affiliations of Jonathan S. Reiner include Case Western Reserve University & Washington University in St. Louis.
Papers
More filters
Journal ArticleDOI
A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial
Allan M. Ross,Karin S. Coyne,Jonathan S. Reiner,Samuel W. Greenhouse,Cynthia A. Fink,Anthony Frey,Eduardo Moreyra,Mouhieddin Traboulsi,Normand Racine,Arthur L. Riba,Mark A Thompson,Steven Rohrbeck,Conor F. Lundergan +12 more
TL;DR: Tailored thrombolytic regimens compatible with subsequent interventions lead to more frequent early recanalization (before cath arrival), which facilitates greater LV function preservation with no augmentation of adverse events.
Journal ArticleDOI
Angiographic Findings and Outcome in Diabetic Patients Treated With Thrombolytic Therapy for Acute Myocardial Infarction: The GUSTO-I Experience
Scott L. Woodfield,Conor F. Lundergan,Jonathan S. Reiner,Samuel W. Greenhouse,Mark A. Thompson,Steven Rohrbeck,Yuri A. Deychak,Maarten L. Simoons,Robert M. Califf,Eric J. Topol,Allan M. Ross +10 more
TL;DR: Early (90-min) infarct-related artery patency as well as regional and global ventricular function do not differ between patients with and without diabetes after thrombolytic therapy, except for reduced compensatory hyperkinesia in the noninfarct zone among patients with diabetes.
Journal ArticleDOI
Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: Mechanism of the “smoker's paradox” from the GUSTO-I trial, with angiographic insights
Gabriel I. Barbash,Jonathan S. Reiner,Harvey D. White,Robert G. Wilcox,Paul W. Armstrong,Zygmunt Sadowsi,Douglas C. Morris,Philip Aylward,Lynn H. Woodlief,Eric J. Topol,Robert M. Califf,Allan M. Ross +11 more
TL;DR: Smokers receiving thrombolysis for acute myocardial infarction presented 11 years earlier than nonsmokers, which generally accounted for their better outcome, and no significant difference in mortality was seen between smokers and nonsmoker.
Journal ArticleDOI
Gender and acute myocardial infarction: is there a different response to thrombolysis?
Scott L. Woodfield,Conor F. Lundergan,Jonathan S. Reiner,Mark A. Thompson,Steven Rohrbeck,Yuri A. Deychak,James O. Smith,Jeffrey R. Burton,William F. McCarthy,Robert M. Califf,Harvey D. White,W. Douglas Weaver,Eric J. Topol,Allan M. Ross +13 more
TL;DR: Women do not differ significantly from men with regard to either early infarct-related artery patency rates or reocclusion after thrombolytic therapy or ventricular functional response to injury/reperfusion, and gender was an independent determinant of 30-day mortality.
Journal ArticleDOI
Extended Mortality Benefit of Early Postinfarction Reperfusion
Allan M. Ross,Karin S. Coyne,E Moreyra,Jonathan S. Reiner,Samuel W. Greenhouse,Pamela L. Walker,Maarten L. Simoons,Yasmine C. Draoui,Robert M. Califf,Eric J. Topol,F. Van de Werf,Conor F. Lundergan +11 more
TL;DR: A substantial mortality advantage for early complete reperfusion (Thrombolysis in Myocardial Infarction [TIMI] grade 3) and for preserved ejection fraction occurred beyond 30 days.